Header
 
Login
 

Privatsphäre-Einstellungen

Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Alle auswählen
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen
Zurück

    Detection of Gabapentin-Lactose Maillard Reaction Product (Schiff’s Base)

    Application to solid dosage form preformulation / Part 2

    Farnaz Monajjemzadeh1,2, Davoud Hassanzadeh1,3, Hadi Valizadeh1,3, Mohammad R. Siahi-Shadbad1,2, Javid Shahbazi Mojarrad1,4, Thomas A. Robertson5, Michael S. Roberts5,6

    1 Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
    2 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
    3 Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran
    4 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
    5 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
    6 Therapeutic Research Centre, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia

    Corresponding author: Dr. Mohammad R. Siahi-Shadbad, Department of Pharmaceutical and Food Control, Tabriz University of Medical Sciences, Tabriz (Iran), Fax +98 (4 11) 3 34 47 98, e-mail: Drsiahi@yahoo.com

    In the following study several techniques are utilized such as Differential Scanning Calorimetery (DSC), Infra-Red (IR) spectroscopy, High Performance Liquid Chromatography (HPLC) and Liquid Chromatography–Mass Spectrometry/Mass Spectrometry (LC-MS/MS) to characterize gabapentin (GBP) and lactose incompatibility in solid state binary mixtures and also in different capsule brands. Solid and aqueous mixtures of the drug and excipient were heated in order to prepare the adduct mixture. Based on the DSC results incompatibility was demonstrated and the imine formation was subsequently evaluated using FTIR spectra. HPLC analysis revealed two extra peaks (compound 1G and 2G) that were fractionated and then injected into LC-MS/MS system. Mass spectra of compound 2G was successfully correlated to GBP-lactose Maillard reaction product. The MRM (Multiple Reaction Monitoring) achieved using a new internal standard and was capable of detecting 4 separate peaks. The LC-MS/MS method was validated and then used for quantifying the amount of remaining drug in the test samples. The presence of lactose in commercial capsules was checked using a TLC method. Overall, the incompatibility of GBP with lactose was successfully evaluated using a combination of thermal methods, FTIR, HPLC and LC-MS/MS.

    Key words Differential scanning calorimetry • Fourier-transform infrared spectroscopy • Gabapentin, lactose incompatibility • High Performance Liquid Chromatograpyh • Lactose, gabapentin incompatibility • Liquid hromatography–mass spectrometry/mass spectrometry • Solid state




    © ECV- Editio Cantor Verlag (Germany) 2011

     

    pharmind 2011, Nr. 2, Seite 376